Drug delivery to the inflammatory brain by enzyme responsive nanoparticles by Bruun, Jonas
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 21, 2017
Drug delivery to the inflammatory brain by enzyme responsive nanoparticles
Bruun, Jonas
Publication date:
2015
Link back to DTU Orbit
Citation (APA):
Bruun, J. (2015). Drug delivery to the inflammatory brain by enzyme responsive nanoparticles. Abstract from
11th International Conference on Cerebral Vascular Biology, Paris, France.
Drug delivery to the inflammatory brain by enzyme responsive nanoparticles  
Aim 
Drug delivery by nanoparticles requires that the particles can encapsulate and protect the drug during 
systemic circulation and then release the drug in the designated region. Qualities that support the first 
requirement often hamper the drug release and uptake in targeted cells. The purpose of this study is to 
design a delivery vehicle responsive to the specific enzyme environment of inflammatory- or stroke-
affected brain so that the enzymatic activity triggers the exposure of a concealed cell penetrating peptide 
(CPP) for increased internalization and drug delivery. 
• Material and methods:  
We have synthesized a lipopeptide composed of a cholesterol anchor and a poly(ethylene glycol) (PEG) 
segment linked by an amino acid sequence which contains a recognition site for matrix metalloproteinase 
(MMP). The responsiveness to enzyme activity of this PEGylated cleavable lipopeptide (PCL) was tested 
with HPLC and MALDI-TOF MS. Liposomes were formulated by hydration and extrusion of a lyophilized lipid 
mixture containing POPC and cholesterol together with a cholesterol anchored short cationic CPP.  The PCL 
was then post-inserted into the liposomes and zeta-potential measurement was utilized to determine the 
surface charge of the liposomes before and after enzyme treatment. The responsiveness to MMP activity 
was also determined in barrier models by cell association studies of fluorescence labeled liposomes. To 
evaluate the drug delivery properties of the PCL liposomes we encapsulated the chemotherapeutic 
oxaliplatin and measured its cytotoxicity when delivered by enzyme responsive and non-responsive 
liposomes. 
 
• Results 
The HPLC and MALDI-TOF analyses showed that the PCL was cleaved in the presence of MMP, both as a 
monomer and when incorporated into a liposome. For PCL incorporated into liposomes, the successful 
cleavage was confirmed by a change in surface charge following enzyme treatment. The PCL was designed 
with negative charges adjacent to the PEG polymer which gave the intact liposome a highly negative 
surface charge. After removal of the PEG-fraction and the negative charges, the underlying cationic CPP 
provided the liposomes with a net positive charge. The differences in surface charge had considerably 
influence on the cellular uptake of the liposomes as the PEGylated, negatively charged liposomes only had 
limited cell association while the enzyme-treated de-PEGylated and positively charged liposomes were 
rapidly internalized by the cells. In the cytotoxicity studies a similar behavior was observed as the 
oxaliplatin was more efficient delivered by MMP responsive liposomes. 
 
• Conclusion  
The incorporation of PCL into the liposome formulation made the liposomes responsive to MMP activity. 
After enzyme treatment the liposomes shifted their surface charge from negative to positive and removed 
their protective PEG coating. This charge shift changed their interaction with cells to a much higher uptake 
and more efficient delivery of the drug.  
 
